-transparent.png){kind=logo}
Transient efficacy of high-dose intravenous immunoglobulin infusions (HDI) is widely demonstrated in autoimmune thrombocytopenic purpura (AITP). A trial involving repeated injections of HDI was conducted in two adult patients with chronic AITP in order to evaluate their long-term efficacy in refractory forms and their ability to obviate splenectomy. Both patients received 2 g/kg body weight of polyvalent intact intravenous immunoglobulin followed by seven and eight boosters (0.8 to 1.2 g/kg body weight) when the platelet count decreased. It was found that the injections could be spaced progressively. The platelet count remained normal 200 and 800 days after the end of the treatment. The demonstration of the possible long-term efficacy of repeated injections of intravenous immunoglobulin encourages us to recommend this safe therapy for patients with chronic AITP.
P Bierling, and
M Divine, and
J P Farcet, and
P Wallet, and
N Duedari
June 1984,
Blut,
P Bierling, and
M Divine, and
J P Farcet, and
P Wallet, and
N Duedari
July 1983,
Scandinavian journal of haematology,
P Bierling, and
M Divine, and
J P Farcet, and
P Wallet, and
N Duedari
June 1983,
Ugeskrift for laeger,
P Bierling, and
M Divine, and
J P Farcet, and
P Wallet, and
N Duedari
November 1997,
American journal of hematology,
P Bierling, and
M Divine, and
J P Farcet, and
P Wallet, and
N Duedari
April 2005,
Human immunology,
P Bierling, and
M Divine, and
J P Farcet, and
P Wallet, and
N Duedari
January 1994,
Acta haematologica Polonica,
P Bierling, and
M Divine, and
J P Farcet, and
P Wallet, and
N Duedari
January 1982,
Clinical and laboratory haematology,
P Bierling, and
M Divine, and
J P Farcet, and
P Wallet, and
N Duedari
February 1995,
Annals of hematology,
P Bierling, and
M Divine, and
J P Farcet, and
P Wallet, and
N Duedari
April 1983,
JAMA,
P Bierling, and
M Divine, and
J P Farcet, and
P Wallet, and
N Duedari
February 1989,
Archives of internal medicine,
